BRAF and melanoma: In contrast to this, we observed synergistic effects of the combined inhibition of BRAF and EZH2 only on melanoma cells resistant to vemurafenib, whereas in susceptible melanoma cells, we observed no additional benefit compared to treatment with vemurafenib alone.